Last reviewed · How we verify
marketed analgesic
At a glance
| Generic name | marketed analgesic |
|---|---|
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain (PHASE3)
- Comparative Study Between Levobupivacaine and Ropivacaine in the Hip Fractures of the Elderly (PHASE4)
- Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury (PHASE2)
- Duloxetine for the Treatment of Chronic Pelvic Pain (PHASE4)
- Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol (PHASE4)
- A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults (PHASE1)
- A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults (PHASE1)
- A Controlled Study of an Herbal Topical Patch in Treating Osteoarthritis (OA) of the Knee (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- marketed analgesic CI brief — competitive landscape report
- marketed analgesic updates RSS · CI watch RSS
- Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI